GUEST COLUMNISTS

  • Solving The 4 Serialization Challenges Of Track & Trace In The Biopharma Industry

    More than 10 years after introducing track and trace, the pharmaceutical industry still faces a number of technical challenges and limitations related to regulatory expectations, with many companies still transforming their packaging operations to meet them.

  • Demystifying Blockchain-Supported Smart Contracts

    Promising increased accuracy, transparency, and security, smart contracts and blockchain technology are the next steps in the evolution of secure data transaction. Companies in the pharmaceutical industry, and their supply chains, will be forced to adapt their operations to keep up with these generational changes in order to competitively deliver services and treatments.

  • Juno v. Kite Case Implications For Functionally Claimed Biological Compositions

    The Federal Circuit recently reversed a jury verdict in the case Juno Therapeutics, Inc. v. Kite Pharma, Inc.., wiping out a $1.2 billion judgment for Juno in the lower court by invalidating claims directed to the functional properties of biological compounds that could be used as therapies. What does this mean for biologics developers going forward?

  • Model-Based Control In Continuous Manufacturing of Biotherapeutics

    During continuous processing, automated control techniques coupled with process analytical tools are required to monitor critical quality attributes and implement real-time control decisions to handle deviations. This article is the first in a two-part series examining how model-based control can be effectively implemented in the various unit operations.

  • Opportunities For Implantable Drug Delivery To Modernize Drug Therapy

    The implantable drug delivery system allows targeted and localized drug delivery for achieving an optimum therapeutic effect. This article examines the clinical significance of implantable drug delivery systems as well as opportunities that can be leveraged by drug therapy developers in meeting global health needs, particularly in the areas of women's health, cancer treatment, and ocular disease treatment.

  • How To Mitigate The Risks Posed By "High-Risk" Host Cell Proteins

    Host cell proteins are process‐related impurities that may copurify with biopharma drug products. Some of these can be considered high-risk, including those that are immunogenic, biologically active, or enzymatically active with the potential to degrade molecules or excipients used in formulation. Here's how to mitigate those risks.

  • Marks Took On FDA Vaccine Leadership Position – What Happens Now?

    Center for Biologics Evaluation and Research Director Dr. Peter Marks decided to temporarily take on the leadership of the Office of Vaccine Research and Review after both its director, Marion Gruber, and deputy director, Philip Krause, unexpectedly announced in late August their decisions to exit the FDA.

  • Calculating The Process Capabilities Of Cleaning Processes: A Primer

    The industry has begun the movement to science-, risk-, and statistics-based approaches to cleaning process development and validation. Process capability has become an important measure for demonstrating acceptable cleaning processe performance. Explore process capability, techniques used for its calculation, and how it's applied to cleaning processes. 

PHARMA OUTSOURCING WHITE PAPERS

louis-new

OUTSOURCED PHARMA CONTENT COLLECTIONS

21_09_OP_CEOEbook_300x200

 

To outsource or not, how much, where and when, have become existential questions of survival, and keys to success (or failure). In our latest e-book, Chief Editor Louis Garguilo looks into how the C-Suite can navigate the complexities involved.

More Content Collections